At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRY ARS PHARMACEUTICALS INC
Trading 03-28 12:23:35 EDT
12.39
-0.24
-1.90%
| High12.78 | Low12.21 | Vol325.58K |
| Open12.63 | D1 Closing12.63 | Amplitude4.51% |
| Mkt Cap1.22B | Tradable Cap587.94M | Total Shares98.12M |
| T/O4.05M | T/O Rate0.69% | Tradable Shares47.45M |
| P/B4.73 | ROE3.28% | EPS0.08 |
| 52wk High18.51 | 52wk Low7.55 | P/E154.88 |
| Dividend0.00 | Div.Yield0.00 | ROA-0.66% |
Stock Track | ARS Pharmaceuticals Plummets 5% as Analysts Slash Revenue and Earnings Forecasts
Stock Track · 03-26 16:30
Stock Track | ARS Pharmaceuticals (SPRY) Plummets 5.02% as Analysts Slash 2025 Forecasts
Stock Track · 03-26 16:30
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year
Simply Wall St. · 03-26 10:16
Stock Track | ARS Pharmaceuticals (SPRY) Surges 5.18% Pre-market on Raymond James' Target Price Hike
Stock Track · 03-24
ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $32 From $28
THOMSON REUTERS · 03-24
Stock Track | ARS Pharmaceuticals Plummets 5.59% Following Q4 Earnings and Analyst Price Target Cut
Stock Track · 03-21
Stock Track | ARS Pharmaceuticals Plummets 5.59% as Q4 Earnings Reveal Slower-Than-Expected Neffy Adoption
Stock Track · 03-21
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
Simply Wall St. · 03-21
ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...
GuruFocus.com · 03-21
Q4 2024 ARS Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents · 03-21
BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly
Reuters · 03-20
ARS Pharma Shares Climb on Surprise 4Q Profit
Dow Jones · 03-20
BUZZ-ARS Pharma rises on surprise Q4 profit
Reuters · 03-20
Stock Track | ARS Pharmaceuticals Soars 20% on Stellar Q4 Results and Strong 2024 Performance
Stock Track · 03-20
ARS Pharmaceuticals Shares up 11.5% After Q4 Revenue Beat
THOMSON REUTERS · 03-20
Sector Update: Health Care Stocks Decline Pre-Bell Thursday
MT Newswires Live · 03-20
ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings
MT Newswires Live · 03-20
Stock Track | ARS Pharmaceuticals Soars 9.44% Pre-Market on Strong Q4 Earnings, Positive Business Updates
Stock Track · 03-20
ARS Pharmaceuticals up 5.8% Premarket After Q4 Results Beat
THOMSON REUTERS · 03-20
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M
MT Newswires Live · 03-20
Introduction
Company Name.
ARS PHARMACEUTICALS INC
Affiliated Markets:
NASDAQ
Listing Date:
2020-12-04
Main Business:
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Issue price:
21.00
Invest in Global Markets with Tiger Brokers!Open App